Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Nov 5, 2014 at 2:00 PM EST

Inotek Pharma Files for IPO

Inotek Pharmaceuticals Corp. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.

Chris Lange | Nov 5, 2014 at 12:00 PM EST

Key Analyst Sees Upside in Medical Devices After Midterm Elections

Oppenheimer has released its list of potential post-election winners in the medical device industry.

Chris Lange | Nov 4, 2014 at 10:10 AM EST

Credit Suisse Sees $70 Billion Biosimilars Land Grab

Credit Suisse released its first edition of the "Credit Suisse Biosimilars 101" series of notes, offering analysis and impact of…

Jon C. Ogg | Nov 3, 2014 at 2:00 PM EST

MannKind Spending Trends See Improvements

MannKind reported its third-quarter financial results on Monday morning.

Chris Lange | Nov 3, 2014 at 12:25 PM EST

Is Geron Back From the Dead?

The FDA gave Geron some good news Monday morning when it removed the clinical hold on the its investigational new…

Chris Lange | Oct 31, 2014 at 11:30 AM EDT

Aegerion Pharmaceuticals Plunges to New 52-Week Low

In the wake of a reported net loss on disappointing sales of its lead product, Aegerion Pharmaceuticals shares lost a…

Chris Lange | Oct 30, 2014 at 2:23 PM EDT

Lakeland Living Up to Production Promises

Lakeland.comLakeland Industries Inc. (NASDAQ: LAKE) gave an update Thursday on its business activity in the wake of the Ebola crisis.…

Lee Jackson | Oct 30, 2014 at 8:55 AM EDT

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to…

Lee Jackson | Oct 29, 2014 at 8:15 AM EDT

Analyst’s Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings

The analysts at Piper Jaffray are very positive on four top specialty pharmaceutical stocks with potential for a strong fourth-quarter…

Chris Lange | Oct 29, 2014 at 7:55 AM EDT

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences reported disappointing third-quarter results after the market close on Monday.

Chris Lange | Oct 28, 2014 at 11:55 AM EDT

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.

Paul Ausick | Oct 27, 2014 at 4:33 PM EDT

Amgen Posts 52-Week High, Beats It Again After Earnings

Amgen reported better-than-expected third-quarter 2014 results after markets closed Monday afternoon.

Chris Lange | Oct 27, 2014 at 12:40 PM EDT

Pain Therapeutics and Durect Stung by Pfizer Move

Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.

Chris Lange | Oct 27, 2014 at 11:10 AM EDT

Sarepta Faces Major Hurdle, and Not From Ebola

Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong…

Chris Lange | Oct 27, 2014 at 10:30 AM EDT

Biotech Short Interest Becomes Stock Specific

Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.

1 … 276 277 278 279 280 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Inotek Pharma Files for IPO

Key Analyst Sees Upside in Medical Devices After Midterm Elections

Credit Suisse Sees $70 Billion Biosimilars Land Grab

MannKind Spending Trends See Improvements

Is Geron Back From the Dead?

Aegerion Pharmaceuticals Plunges to New 52-Week Low

Lakeland Living Up to Production Promises

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Analyst’s Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

What to Look For in Gilead Sciences Earnings Report

Amgen Posts 52-Week High, Beats It Again After Earnings

Pain Therapeutics and Durect Stung by Pfizer Move

Sarepta Faces Major Hurdle, and Not From Ebola

Biotech Short Interest Becomes Stock Specific

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Gold Slides, 30-Year Yield Hits 5.1% as Rate Fears Take Over

Coinbase Has 26% Upside to Price Targets After 57% Selloff

Alphabet Eyes 20% Upside as Cloud Backlog Surges

"If a 2% Market Move Makes You Question Your Retirement Plan, You Don't Have One"

A $1 Million Portfolio That Quietly Pays You $4,600 a Month, No Job Required

Gold Slides, 30-Year Yield Hits 5.1% as Rate Fears Take Over

Coinbase Has 26% Upside to Price Targets After 57% Selloff

Health and Healthcare Articles

All Health and Healthcare Articles

Inotek Pharma Files for IPO

Key Analyst Sees Upside in Medical Devices After Midterm Elections

Credit Suisse Sees $70 Billion Biosimilars Land Grab

MannKind Spending Trends See Improvements

Is Geron Back From the Dead?

Aegerion Pharmaceuticals Plunges to New 52-Week Low

Lakeland Living Up to Production Promises

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Analyst’s Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

What to Look For in Gilead Sciences Earnings Report

Amgen Posts 52-Week High, Beats It Again After Earnings

Pain Therapeutics and Durect Stung by Pfizer Move

Sarepta Faces Major Hurdle, and Not From Ebola

Biotech Short Interest Becomes Stock Specific

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Gold Slides, 30-Year Yield Hits 5.1% as Rate Fears Take Over

Coinbase Has 26% Upside to Price Targets After 57% Selloff

Alphabet Eyes 20% Upside as Cloud Backlog Surges

Featured Reads

"If a 2% Market Move Makes You Question Your Retirement Plan, You Don't Have One"

A $1 Million Portfolio That Quietly Pays You $4,600 a Month, No Job Required